DK1180028T3 - IL-8-receptorantagonister - Google Patents

IL-8-receptorantagonister

Info

Publication number
DK1180028T3
DK1180028T3 DK00936369T DK00936369T DK1180028T3 DK 1180028 T3 DK1180028 T3 DK 1180028T3 DK 00936369 T DK00936369 T DK 00936369T DK 00936369 T DK00936369 T DK 00936369T DK 1180028 T3 DK1180028 T3 DK 1180028T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
DK00936369T
Other languages
Danish (da)
English (en)
Inventor
Michael R Palovich
Katherine L Widdowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK1180028T3 publication Critical patent/DK1180028T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00936369T 1999-05-28 2000-05-26 IL-8-receptorantagonister DK1180028T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13671799P 1999-05-28 1999-05-28
PCT/US2000/014661 WO2000072845A1 (en) 1999-05-28 2000-05-26 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
DK1180028T3 true DK1180028T3 (da) 2007-05-21

Family

ID=22474057

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00936369T DK1180028T3 (da) 1999-05-28 2000-05-26 IL-8-receptorantagonister

Country Status (27)

Country Link
US (1) US6566387B1 (no)
EP (1) EP1180028B1 (no)
JP (1) JP2003500447A (no)
KR (1) KR20020010674A (no)
CN (1) CN1353606A (no)
AR (1) AR029637A1 (no)
AT (1) ATE352299T1 (no)
AU (1) AU766082B2 (no)
BR (1) BR0010843A (no)
CA (1) CA2375683A1 (no)
CO (1) CO5170514A1 (no)
CZ (1) CZ20014247A3 (no)
DE (1) DE60033145T2 (no)
DK (1) DK1180028T3 (no)
ES (1) ES2280217T3 (no)
HK (1) HK1045257A1 (no)
HU (1) HUP0201300A3 (no)
IL (1) IL146046A0 (no)
MX (1) MXPA01012268A (no)
NO (1) NO20015775D0 (no)
NZ (1) NZ514729A (no)
PL (1) PL351946A1 (no)
PT (1) PT1180028E (no)
SI (1) SI1180028T1 (no)
TR (1) TR200103448T2 (no)
WO (1) WO2000072845A1 (no)
ZA (1) ZA200109628B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495569B1 (en) * 2001-04-19 2002-12-17 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2006043950A1 (en) * 2004-10-20 2006-04-27 Smithkline Beecham Corporation Il-8 receptor antagonists
EP2009992B1 (en) * 2006-04-21 2012-06-27 GlaxoSmithKline LLC Il-8 receptor antagonists
EP2010180A4 (en) * 2006-04-21 2010-10-13 Glaxosmithkline Llc IL-8 RECEPTOR ANTAGONISTS
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335352B1 (en) * 1996-08-15 2002-01-01 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1998006262A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2001501172A (ja) * 1996-08-15 2001-01-30 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８レセプターアンタゴニスト
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
EP0939634A4 (en) 1996-08-15 2001-02-21 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
TR199901710T2 (xx) 1997-01-23 1999-09-21 Smithkline Beecham Corporation IL-8 resept�r antagonistleri.
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8

Also Published As

Publication number Publication date
EP1180028A4 (en) 2002-10-23
HK1045257A1 (zh) 2002-11-22
NO20015775L (no) 2001-11-27
US6566387B1 (en) 2003-05-20
DE60033145T2 (de) 2007-10-31
MXPA01012268A (es) 2002-07-30
EP1180028B1 (en) 2007-01-24
HUP0201300A2 (hu) 2002-12-28
NO20015775D0 (no) 2001-11-27
EP1180028A1 (en) 2002-02-20
CA2375683A1 (en) 2000-12-07
BR0010843A (pt) 2002-02-19
PT1180028E (pt) 2007-04-30
TR200103448T2 (tr) 2002-06-21
SI1180028T1 (sl) 2007-06-30
CO5170514A1 (es) 2002-06-27
ZA200109628B (en) 2002-11-22
AU5169100A (en) 2000-12-18
HUP0201300A3 (en) 2003-02-28
CN1353606A (zh) 2002-06-12
KR20020010674A (ko) 2002-02-04
WO2000072845A1 (en) 2000-12-07
JP2003500447A (ja) 2003-01-07
DE60033145D1 (de) 2007-03-15
CZ20014247A3 (cs) 2002-05-15
AU766082B2 (en) 2003-10-09
ES2280217T3 (es) 2007-09-16
ATE352299T1 (de) 2007-02-15
NZ514729A (en) 2003-11-28
IL146046A0 (en) 2002-07-25
AR029637A1 (es) 2003-07-10
PL351946A1 (en) 2003-07-14

Similar Documents

Publication Publication Date Title
NO20001100D0 (no) IL-8 reseptorantagonister
NO20025754D0 (no) IL-8 Reseptor-antagonister
DE60216229D1 (de) Il-8-rezeptorantagonisten
NO20016053L (no) IL-8 reseptor-antagonister
ATE299698T1 (de) Il-8 rezeptor antagonisten
ATE353215T1 (de) Il-8 rezeptor-antagonisten
NO20016052D0 (no) IL-8-reseptor-antagonister
DE69838874D1 (de) Il-8 rezeptor-antagonisten
NO20024554D0 (no) IL-8 reseptorantagonister
DK1180028T3 (da) IL-8-receptorantagonister
DE69831413D1 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20015774D0 (no) IL-8 reseptorantagonister
NO20024367D0 (no) IL-8 reseptorantagonister
NO20016102L (no) IL-8 reseptorantagonister
NO20016065D0 (no) IL-8-reseptor-antagonister
NO20024366D0 (no) IL-8 reseptorantagonister
NO20010353D0 (no) IL-8 reseptor-antagonist
SE0003996D0 (sv) Receptorantagonister